Safety of enoxaparin in patients implanted with continuous flow left ventricular assist devices.

ABSTRACT:

Background

The objective of this study is to determine the incidence of major bleeding events in patients implanted with continuous flow left ventricular assist devices (CF-LVADs) bridged with enoxaparin (LMWH) compared to intravenous unfractionated heparin (IV UFH) for a subtherapeutic INR on warfarin.

Methods

A single-center, retrospective, cohort study was conducted including patients with CF-LVADs implanted between January 1, 2012 and July 1, 2020 who received at least one inpatient dose or outpatient prescription for LMWH or IV UFH at least 60 days after CF-LVAD implantation. The primary endpoint was the incidence of major bleeding.

Results

In total, 176 orders were screened and 90 orders in 62 unique patients were included. Major bleeding and thromboembolic even

SUBMITTER: Klosko RC 

PROVIDER: S-EPMC11974480 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature